Key Highlights

  • Q2 was a genuine beat, $6.6bn of sales, 9.0% organic growth and $3.69 adjusted EPS, but a $158m Reversal of 2025 tariffs inflated reported profit and will not repeat.
  • The sell-off was about the guidance ceiling coming down to 9.3% organic growth while the maths still demands roughly 11% organic growth in the second half.
  • At about 20.3 times forward Earnings , Stryker carries a large premium to Zimmer Biomet and Boston Scientific, leaving little tolerance for further operational slippage.
  • Stryker reported second-quarter 2026 net sales of $6.6bn on 30 July, up 9.4% as reported and 9.0% organically, with adjusted earnings of $3.69 a share against a consensus near $3.49.

A guidance trim that outweighed a clean beat

Stryker (NYSE:SYK) reported second-quarter 2026 net sales of $6.6bn on 30 July, up 9.4% as reported and 9.0% organically, with adjusted earnings of $3.69 a share against a consensus near $3.49. On the surface this was the quarter the market had been waiting for since a March cyberattack knocked out order processing, shipping and Manufacturing for roughly a month.

Investors fixed on something else. Management narrowed full-year Organic Sales growth guidance to 8.3%–9.3%, from the 8.0%–9.5% range reaffirmed in April, and set adjusted EPS at $14.95–$15.10 versus $14.90–$15.10 previously. The floor came up; the ceiling came down. After first-half organic growth of 2.4% in Q1 and 9.0% in Q2, hitting the full-year range now requires acceleration to roughly 11% in the second half, a step-up that depends on shipping recovered Backlog rather than on new Demand . Trimming the upside case while asking the market to underwrite that ramp proved an awkward combination.

The tape: a one-day repricing on top of a bad year

Shares closed at $325.70 on Friday 31 July, down $22.34 or 6.42%, cutting market Capitalization to about $124.9bn. Press reports published during the session quoted declines between 5.8% and 7.5%, a reminder that the stock traded lower still before recovering into the close.

The single-day move sits inside a much weaker stretch. SYK has fallen 18.7% over twelve months and trades 19% below its 52-week high of $401.99, against a low of $281.00. For a name whose appeal rests on predictable high-single-digit growth and steady multiple expansion, that de-rating is the more consequential fact.

What Stryker actually sells

The Business splits into two roughly equal halves. MedSurg and Neurotechnology contributed $3.625bn in the quarter and covers surgical instruments, endoscopy and imaging, hospital beds and stretchers, neurovascular devices and, since the 2025 Acquisition of Inari Medical for about $4.9bn, peripheral vascular thrombectomy. Orthopaedics contributed $2.964bn across knees, hips, trauma and extremities, and spine.

The connective tissue is Mako, Stryker's robotic surgery platform. Placing a Mako system inside a hospital or ambulatory surgery center effectively locks in years of implant purchases, because the robot is engineered around Stryker's own knee and hip systems. That razor-and-blade dynamic is why capital placements matter far more than their direct Revenue contribution suggests, and why Stryker has spent a decade extending the platform into new anatomy.

Inside the quarter's numbers

Growth was broad rather than concentrated. MedSurg and Neurotechnology grew 9.2% organically, led by Medical at 13.4% and Endoscopy at 11.7%, both categories where the post-cyberattack production catch-up is most visible. Orthopaedics grew 8.6% organically, with trauma and extremities up 11.9% and knees up 8.4%. International sales rose 11.0%, outpacing US growth of 8.9%.

Two blemishes stand out. Vascular sales of $496m fell 0.7% after a manufacturing problem at an Inari plant created backorders and lost sales; management put the drag at roughly 50 to 75 basis points of company organic growth and expects backlogs to normalize by the end of Q3. Hips grew just 2.9%, with US hips up 4.9% against a demanding prior-year comparison.

Profitability flattered the headline. Reported EPS of $3.30 rose 44.1%, but that figure includes a $158m reversal of 2025 tariffs booked to Gross Profit , a one-time item that lifted the reported gross Margin to 68.3%. Stripping it out, adjusted gross margin was 66%, up 60 basis points, and adjusted Operating Margin reached 27.4%, up 170 basis points. That underlying 170-point expansion is the genuinely impressive number, achieved while absorbing cyber remediation costs that management says will persist through the rest of 2026. Year-to-date Operating Cash Flow was $1.8bn, cash and securities stood near $3.5bn against total Debt of $14.19bn, and the company said it would resume Buybacks in the second half using roughly $1bn of existing authorization, while keeping M& Amp ;A as its first call on capital.

Mako, and the robot in the room

Stryker passed 2.5 million cumulative Mako procedures across 47 countries by July, and management described the quarter as its best-ever Q2 for Mako installations in both the US and international markets. Mako 4, launched with applications spanning total hip, total knee, partial knee and spine, has since been joined by Mako Shoulder.

The more interesting move is Mako RPS, a handheld robotic system for total knee replacement that entered full market release, pairing a robotically enabled saw with the established Triathlon knee implant. Rather than requiring the full capital footprint and workflow change of an arm-based robot, RPS targets surgeons who want robotic accuracy inside a conventional workflow, particularly in ambulatory surgery centers, where capital budgets are tighter and throughput matters more. If it converts competitive users, it widens the funnel for Stryker implants without cannibalizing the flagship platform. Early volumes remain small.

The case for owning the recovery

The bull argument is that the demand signal never broke. Management characterized the capital order book as carrying elevated backlog with no cancellations, which reframes the second-half ramp as a manufacturing and logistics problem rather than a market one. Add the Tariff reversal falling away, cyber costs rolling off into 2027, an 170-basis-point margin trajectory, a resumed buyback, and a robotics installed base that compounds implant pull-through, and the case for growth reacceleration is not exotic.

What the bears are pointing at

The counter is that too much of Q2 was non-repeatable. The tariff refund is gone, the Inari Supply issue is unresolved until late Q3, and the implied 11% second-half organic growth leaves no cushion for another operational surprise from a company that has just proved its supply chain can be taken offline by an outside actor. Hip growth of 2.9% raises a competitive question in a category Stryker has historically won. BTIG, which kept a buy rating, still cut its target to $358 from $371, citing the size of the required second-half step-up.

Paying up for compounding

At $325.70 the shares trade on about 20.3 times forward earnings, 5.25 times Enterprise value to revenue, 20.1 times EV/EBITDA and 26.6 times free cash flow, for a 3.8% free cash flow Yield and a 1.08% Dividend Yield on $3.52 a share. That remains a clear premium to orthopedic peer Zimmer Biomet at roughly 11 times forward earnings and to Boston Scientific near 14 times. The premium is defensible on growth and Mako's moat, but it means execution errors get punished quickly, which is essentially what happened on 31 July. The 28-analyst consensus target sits at $383.08.

What to watch from here

Three things determine whether the de-rating reverses: whether Inari backorders clear by the end of September, whether third-quarter organic growth actually prints near the 11% the guidance implies, and whether Mako RPS placements show up in the installation count. Anything short on the first two makes the full-year range look optimistic rather than conservative.

Upcoming Catalysts

  • Q3 2026 results, expected late October 2026. The first clean read on whether the implied second-half acceleration toward 11% organic growth is achievable.
  • Inari vascular Backorder clearance, targeted by end of Q3 2026. Management expects backlogs at manageable levels; failure would extend the 50–75 basis point drag on group organic growth.
  • Mako RPS commercial ramp, from the full market release. Watch whether the handheld system converts competitive knee surgeons in ambulatory surgery centers.
  • Resumption of share repurchases in H2 2026. Roughly $1bn of existing authorization, with M&A still management's stated first priority for capital.

Principal Risks

  • Second-half execution. Guidance now depends on manufacturing and shipping recovered backlog at pace; any further supply interruption puts the full-year range out of reach.
  • Residual cyberattack costs. Remediation and IT stabilization expenses from the March 2026 incident continue through the rest of 2026, and the episode exposed a single point of failure across order processing, shipping and manufacturing.
  • Inari integration. The $4.9bn acquisition has produced a plant problem and a 0.7% vascular sales decline in its first full year inside the portfolio.
  • Valuation compression. A premium multiple against slower-growing device peers means disappointment is repriced sharply, as the 6.42% single-session fall demonstrated.
  • Orthopedic competition and reimbursement. Hip growth of 2.9% invites questions about share, and hospital capital budgets remain sensitive to Medicare payment policy.

Conclusion

Q2 was a genuine beat, $6.6bn of sales, 9.0% organic growth and $3.69 adjusted EPS, but a $158m reversal of 2025 tariffs inflated reported profit and will not repeat. Set against that: Guidance now depends on manufacturing and shipping recovered backlog at pace; any further supply interruption puts the full-year range out of reach. That tension shows up in the valuation: At about 20.3 times forward earnings, Stryker carries a large premium to Zimmer Biomet and Boston Scientific, leaving little tolerance for further operational slippage. The next real test: The first clean read on whether the implied second-half acceleration toward 11% organic growth is achievable.

This article is for informational purposes only and does not constitute Investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.